China Chongqing Zhifei Biological Products Company announced on the 27th that its recombinant protein coronavirus vaccine has obtained the third phase of clinical trials and showed that the protection rate against the coronavirus is 81.76%. It is also effective for Delta variant viruses.
It was reported that Chongqing Zhifei Biological Products Co., Ltd. issued an announcement stating that the company’s wholly-owned subsidiary Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences jointly developed a new recombinant vaccine (CHO cell). Key data from Phase III clinical trials. This is China’s first recombinant protein vaccine to publish clinical Phase III data.
According to the announcement, since December 12 last year, the vaccine has successively carried out international multi-center clinical trials in Hunan Province, Uzbekistan, Indonesia, Pakistan and Ecuador. 28,500 people were actually enrolled, including 14,251 cases in the vaccine group and 14,249 cases in the placebo group.
The announcement stated that a total of 221 cases of the primary endpoint after the whole course of vaccination were monitored, and the protective efficacy for any severity of coronary disease was 81.76%, which met the vaccine effectiveness standards required by the World Health Organization. Among them, the protection effect for severe and above cases and death cases is 100%.
Preliminary genotyping analysis results showed that the vaccine’s protective efficacy against Alpha mutant strains was 92.93%, and the protective efficacy against Delta mutant strains was 77.54%.
According to reports, Zhifei Biological Vaccine was put into emergency use in March this year. It is the fourth coronavirus vaccine approved for emergency use in China and the first recombinant coronavirus subunit protein vaccine approved for clinical use in the world.
At present, facing the pressure of the pandemic abroad, China is stepping up the immunization of the COVID-19 vaccine, but it also faces the problem that many people cannot vaccinate.
The Paper reported that Taiyuan in Shanxi, Jingchuan in Gansu, Yizhang in Hunan, and Siping in Jilin recently introduced relevant regulations to standardize the diagnosis of vaccination contraindications, requiring all relevant medical institutions to form an expert group to determine if there are indeed contraindications to vaccination and underlying diseases. Persons in such circumstances are assessed by classification and classification, and the certification of real vaccination contraindications or suspension of vaccination shall be standardized. If fraudulent, the doctor will be held accountable.
China Times reported that a 47-year-old man from New Taipei City, Taiwan suffered an adverse reaction after receiving high-end vaccines on the 24th, and died on the 26th. Another 40-year-old woman with chronic diseases in the same city passed out on the 27th and died after being vaccinated on the 23rd. Since Taiwan launched a “high-end” vaccine on the 23rd, there have been 6 deaths in 5 days. Source